Navigation Links
Konelab 20XT

ProductsKonelab 20XT
Company ThermoFisher Scientific
Item Konelab 20XT
Features 
  • 84 sample positions with continuous loading segments
  • 5 STAT positions
  • 35 reagent positions, real-time reagent status seen
  • 50 cuvettes on-board, 2.5 hours walk-away time
Description The Konelab 20XT analyzer is the newest addition to the Konelab family of clinical chemistry analyzers and reagents, designed to meet the needs of medium and small routine and specialty clinical laboratories. The Konelab 20XT analyzer has the same compact size as Konelab 20 and yet improves on the throughput, while providing frames for optimized special testing.
Info ThermoFisher Scientific
Web site: http://www.thermo.com
Web site: http://www.thermofisher.com/global/en/home.asp

Related medicine products :

1. Konelab 20
2. Konelab 60
3. Konelab 30
TAG: Konelab
... A necessary addition to ... the Reichert Trial Frame ... and smooth controls for ... robust design, high-quality materials, ...
... The Ultramatic Rx Master is ... years of reliable service and ... that measurably improve procedures. It ... need and want most, including ...
The Maverick Over-The-Wire balloon catheter delivers a new level of performance to meet the changing demands of interventional cardiology....
... Illumination is provided by a cool-running, ... light only what you need to see ... best of all they are maintenance free ... light bulb. Every Phoroptor comes with a ...
Medicine Products:
Breaking Medicine News(10 mins):Health News:Thomson Reuters Releases Micromedex 2.0 2Health News:Thomson Reuters Releases Micromedex 2.0 3Health News:Drummond Group Awarded DOE Funds for Texas Wind Integration Project 2Health News:Drummond Group Awarded DOE Funds for Texas Wind Integration Project 3Health News:Drummond Group Awarded DOE Funds for Texas Wind Integration Project 4Health News:Online Medical Supply Superstore Adds Cure Catheters to Product Mix 2Health News:Pixantrone Produces 250% Relative Improvement in 1 Year Progression Free Survival for Patients With Relapsed/Refractory, Aggressive Non-Hodgkin's Lymphoma Across All Measured Risk Factors - Updated Follow-Up Data 2Health News:Pixantrone Produces 250% Relative Improvement in 1 Year Progression Free Survival for Patients With Relapsed/Refractory, Aggressive Non-Hodgkin's Lymphoma Across All Measured Risk Factors - Updated Follow-Up Data 3Health News:Pixantrone Produces 250% Relative Improvement in 1 Year Progression Free Survival for Patients With Relapsed/Refractory, Aggressive Non-Hodgkin's Lymphoma Across All Measured Risk Factors - Updated Follow-Up Data 4Health News:Pixantrone Produces 250% Relative Improvement in 1 Year Progression Free Survival for Patients With Relapsed/Refractory, Aggressive Non-Hodgkin's Lymphoma Across All Measured Risk Factors - Updated Follow-Up Data 5Health News:Recognized Top Performers in UHC Supply Chain 2
Breaking Medicine Technology:RetireSafe Urges Senate to Defeat Senate Amendment 2793 -- Says Senator Dorgan's Drug Importation Plan Puts Seniors at Risk 2AcceleDent Science is Showcased in New Continuing Education Course Published by PennWell 2AcceleDent Science is Showcased in New Continuing Education Course Published by PennWell 3AcceleDent Science is Showcased in New Continuing Education Course Published by PennWell 4Northwest Biotherapeutics Receives Approval of US Patent for Cost Saving Automation of High-Concentration DCVax(R) Manufacturing 2Northwest Biotherapeutics Receives Approval of US Patent for Cost Saving Automation of High-Concentration DCVax(R) Manufacturing 3Northwest Biotherapeutics Receives Approval of US Patent for Cost Saving Automation of High-Concentration DCVax(R) Manufacturing 4Northwest Biotherapeutics Receives Approval of US Patent for Cost Saving Automation of High-Concentration DCVax(R) Manufacturing 5Fraunhofer CSE Opens First Laboratory in Cambridge MA 14456 1Fraunhofer CSE Opens First Laboratory in Cambridge MA 14456 2Fraunhofer CSE Opens First Laboratory in Cambridge MA 14456 3Amylin Pharmaceuticals to Webcast Third Quarter Results 14453 1Amylin Pharmaceuticals to Webcast Third Quarter Results 14453 2Minimally Invasive Device Approved to Treat Liver Cancer Fibroids Tumors and Bleeding 5449 1Minimally Invasive Device Approved to Treat Liver Cancer Fibroids Tumors and Bleeding 5449 2Minimally Invasive Device Approved to Treat Liver Cancer Fibroids Tumors and Bleeding 5449 3